Morgan Stanley raised the firm’s price target on Amrize (AMRZ) to $61 from $60 and keeps an Overweight rating on the shares. Good cash generation, volume growth and margin progression added up to an improved Q3 following a “disappointing” Q2, the analyst tells investors in a post-earnings note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ: